Yet, the authors demonstrated that the use of GLP-1 RAs (mostly semaglutide or liraglutide) as an add-on treatment to insulin resulted in a statistically significant reduction in HbA1c, body weight, BMI and basal insulin dose in T1D patients during an 18-month follow-up period. This evidence concerns the gene INS and type 1 diabetes mellitus.